|
|
||||||||
Ann Thorac Surg 2002;73:64-68
© 2002 The Society of Thoracic Surgeons
a Sections of Cardiothoracic Surgery and Cardiology, St. Christophers Hospital for Children, Philadelphia, Pennsylvania, USA
b Department of Surgery, Deborah Heart and Lung Center, Browns Mills, New Jersey, USA
* Address reprint requests to Dr Jacobs, Section of Cardiothoracic Surgery, St. Christophers Hospital for Children, Erie Ave at Front St, Philadelphia, PA 19134, USA
Presented at the Thirty-seventh Annual Meeting of The Society of Thoracic Surgeons, New Orleans, LA, Jan 2931, 2001.
| Abstract |
|---|
|
|
|---|
Methods. From January 1996 through December 2000, 72 patients underwent Fontan procedures. Management included (1) avoidance of direct caval cannulation and central venous lines, (2) inotropic support for 48 to 72 hours to optimize cardiac output, (3) aortopulmonary anastomosis or suture closure of patent pulmonary valves, and (4) administration of aspirin (81 mg per day) beginning on postoperative day one. No other anticoagulation strategies were used. Surveillance included intraoperative and postoperative transesophageal echo, transthoracic echo at discharge, at first reevaluation, and at 6 month intervals, and catheterization 1 year after surgery.
Results. There were no early or late deaths. Follow-up was completed with 2,882 patient-months and a mean of 40 months. There were no documented thromboembolic events; however, all suspicious occurrences were investigated by echo and brain imaging. There were no hemorrhagic events or aspirin-related complications.
Conclusions. Low dose aspirin can be used safely in young patients with Fontan connections. At intermediate follow-up, the strategies described appear effective in preventing thromboembolic complications. Routine use of more aggressive anticoagulation regimens seems unwarranted.
| Introduction |
|---|
|
|
|---|
In 1998, Monagle and associates [26] reviewed the literature on thromboembolic complications after Fontan procedures. They concluded that much of the extant data was anecdotal, and suggested that multicenter randomized controlled trials comparing prophylactic antiplatelet and anticoagulation therapies could provide important information to guide the management of patients who undergo Fontan procedures. In the absence of such randomized trials, we offer our retrospective evaluation of the results of a scheme of Fontan patient management, including aspirin therapy, that has been applied consistently in our practice for more than 5 years.
| Patients and methods |
|---|
|
|
|---|
Several additional features of the operative plans were intended to reduce the likelihood of thromboembolism. No central venous lines were placed. Bypass was started with a dilute blood prime using a single venous cannula in the right atrium with a pump return to the ascending aorta. No direct caval cannulations were used, and no tourniquets were placed around the inferior or superior vena cava. Total cavopulmonary connection was accomplished as described [27] during a period of hypothermic circulatory arrest. After rewarming, infusions of Dopamine or Dobutamine, or both were started at 2 to 7 mcg/kg per minute, ventilation was increased, and bypass was discontinued. For purposes of hemodynamic monitoring and infusions, two 18-gauge polyvinyl catheters were inserted through the right atrial cannulation site with the tips situated in the pulmonary venous portion of the right atrium. They were exteriorized through the chest wall. No catheters were placed in the venous pathway or the pulmonary arteries. Following reversal of heparin with protamine (6 to 10 mg/kg with a goal of achieving the patients baseline activated clotting time), fresh whole blood (less than 48 hours old, citrated) was administered to replenish intravascular volume and restore adequate coagulation. No patient received aprotinin, epsilon amino caproic acid, or platelet concentrates. A single anterior mediastinal chest tube was placed, and primary sternal closure was achieved in routine fashion. Patients were extubated in the intensive care unit as they emerged from anesthesia if hemodynamics were stable and bleeding was minimal. Postoperative pleural fluid collections were drained using 7 French polyvinyl catheters placed using the Seldinger technique. Aspirin was administered at a dose of 81 mg by mouth daily, beginning on the first postoperative day. To optimize cardiac output, inotropic support was continued at gradually diminished doses for a minimum of 48 hours.
Each patient underwent transesophageal echocardiography at the time of separation from cardiopulmonary bypass or within a few hours of admission to the intensive care unit. Transthoracic echocardiography was then performed prior to discharge, at the first outpatient reevaluation, and thereafter at 6-month intervals. Complete hemodynamic assessments by heart catheterization and angiography were performed 1 year after surgery. In addition to the routine postoperative surveillance, any suspicious events possibly thought to be the consequence of thromboembolism were investigated by transthoracic ± transesophageal echocardiography and by imaging studies of the brain (computed tomographic scan ± magnetic resonance imaging). In addition to this surveillance protocol, current information with regard to each patient was obtained by means of a telephone survey and a mailed questionnaire from October 2000 through December 2000. Follow-up was considered current if contact was successfully achieved with a parent and the patients primary cardiologist.
| Results |
|---|
|
|
|---|
|
The telephone survey and questionnaire resulted in contact with a parent or surrogate of every patient, and with the primary cardiologist of all except 2 patients. As there is current data on all patients, this constitutes 2,882 patient-months of follow-up, with an average duration of follow-up of 40 months. Sixty-nine of 72 patients remain on daily aspirin, and 1 patient is on aspirin (81 mg) every other day. Two patients no longer take aspirin on a regular basis. In most instances the surveillance recommendations were observed at the discretion of their primary cardiologist, although several patients (after more than 2 years post-Fontan operations) now have echocardiograms every year rather than every 6 months. Catheterization with cardiac angiography was performed about 1 year after Fontan operations on 54 patients.
There were no early postoperative deaths and no late deaths. There have been no hemorrhagic events or aspirin-related complications. No patient has taken warfarin or other nonaspirin anticoagulant. There have been no documented thromboembolic events. Two suspicious events were investigated, and thromboembolism was ruled out. A 4-year-old girl with complex transposition of the great arteries experienced self-limited seizures during a febrile illness 2 years after the completion Fontan procedure. Echocardiography showed no evidence of thrombus or thromboembolism and no evidence of right to left shunt. The brain computed tomographic scan was normal. A subsequent magnetic resonance image showed no evidence of thromboembolic phenomena. A 4-year-old boy with single left ventricle had a 4-hour loss of consciousness followed by seizures after a fall with closed head trauma. An emergent brain computed tomographic scan was done and was found to be normal. Echocardiography showed no evidence of thrombus or thromboembolism and no evidence of right to left shunt. Subsequent brain magnetic resonance imaging showed small hemangiomas and no evidence of infarction.
| Comment |
|---|
|
|
|---|
In our patients, the consistent use of low dose aspirin after Fontan operations is based in part upon experimental work by Pearl and colleagues [29] that demonstrated aspirin delayed but did not prevent the spontaneous closure of fenestrations in a PTFE atrial septal substitute in a canine experimental model. Importantly, they showed that closure was accomplished primarily through the ingrowth of fibrous tissue, and not as a result of thrombosis. Unlike warfarin, the regular administration of low-dose aspirin to children extracts very little in the way of cost, inconvenience, adverse side effects, or the need for monitoring.
We do not attribute the absence of clinically evident thromboembolic complications in our series to the use of aspirin alone. The operations as described are designed to minimize the potential for distortion and disruption of smooth endothelial surfaces in the venous pathways. The avoidance of direct caval cannulation requires the use of brief periods of hypothermic circulatory arrest. As pointed out by Mosca and colleagues [30], this strategy not only avoids caval distortion, but also obviates the need for dissection around the superior and inferior vena cava. This potentially reduces problems from bleeding and from phrenic nerve injury. Avoidance of central venous catheters is based on the observation that these frequently serve as the nidus for initiation of platelet and fibrin thrombi. The use of only transthoracic atrial lines permits continuous monitoring of cardiac filling pressures during the early postoperative period, without the additional presence of foreign bodies in the cavopulmonary pathway. In no patient was the removal of these lines after the initiation of aspirin therapy associated with significant blood loss. The routine use of inotropic agents during the first 48 to 72 hours is intended to optimize cardiac output during this crucial period, although most patients could be successfully separated from cardiopulmonary bypass without pharmacologic support. The use of small percutaneous catheters to drain pleural fluid collections facilitates early mobilization because these do not need to be attached to continuous drainage systems but may alternatively be aspirated using a syringe and stopcock system.
The potential contribution of baffle fenestration and persistent right to left shunts to the incidence of thromboembolic complications is a matter of speculation. We are convinced that the early postoperative state of Fontan patients is improved by baffle fenestration, resulting in less difficulty optimizing cardiac output and less morbidity from effusions. We choose in most instances to create a lateral atrial tunnel with multiple small fenestrations, and we have demonstrated that these fenestrations undergo spontaneous closure, usually within 1 year [31]. This strategy confers the early postoperative benefits of fenestration while limiting the duration of the persistence of right-to-left shunting. This strategy also eliminates the need for subsequent use of catheter delivered intracardiac devices to accomplish fenestration closure. The use of such devices may increase the overall risk of thromboembolic complications.
We do not take issue with those who suggest that multiinstitutional randomized controlled trials would be the most scientific method to arrive at recommendations for anticoagulation therapy after Fontan operations. Nor do we suggest that routine administration of low-dose aspirin will entirely eradicate these important morbid complications. We are however, significantly encouraged by the 5-year experience reported here in this study. Of course the study is limited by its retrospective nature and lack of a control group. The consistent young ages of the patient population leave the questions open regarding the impact of such a strategy on older patients and on these patients as they age and undergo normal maturational changes of the coagulation system. Furthermore, we acknowledge that more sensitive, though more invasive means of investigation might possibly have revealed clinically silent thrombi in our patients. Clearly, the possibility exists that patients may experience small pulmonary emboli that are not clinically apparent, and that they may in fact lyse spontaneously without specific therapy. Fyfe and colleagues [16] have shown that transesophageal echocardiography is more sensitive than transthoracic echocardiography as a tool to detect thrombi in Fontan pathways. Intravascular ultrasound still may be more sensitive. However, in the absence of adverse clinical outcomes because of thromboembolic complications, the surveillance we recommend and use seems efficacious.
We infer from our experience that low-dose aspirin can be used safely in young patients with these types of Fontan connections. At intermediate follow-up the strategies described appear effective in preventing thromboembolic complications. Routine use of more aggressive anticoagulation regimens seem unwarranted.
| Footnotes |
|---|
|
|
|---|
| Discussion |
|---|
|
|
|---|
What I would like to ask you is based on your review of the literature and the information from your own patients. I was impressed with that fact that you presented that two-thirds of the thromboembolic events reported in the literature occurred in the first year after the Fontan operation. Based on that very significant analysis, and your own analysis, what do you think about a strategy of keeping Fontan patients on Coumadin therapy for the first year following the Fontan and then converting them to aspirin therapy following that?
DR JACOBS: Actually, that is a very good question. The review of the literature, as I mentioned, goes back to 1978. A lot of these early case reports involved thrombosis of a conduit between the right atrial appendage and the left pulmonary artery in patients with prior Glenn anastomosis, or thrombosis in hugely enlarged right atria following atriopulmonary anastomoses. So I think that the merit of an anticoagulant strategy is really related to the technique by which the operation is done. And certainly I would not want to suggest that the routine use of aspirin would be adequate for all Fontan patients with all types of connections, particularly those that we have largely abandoned because of the technical complications associated with them.
However, I would have thought that even with a small series like this, that if aspirin anticoagulation was inadequate to prevent thromboembolic complications during the first year, that this experience would have shown us some evidence of that with an adverse clinical outcome, and we didnt see any.
DR BACKER: My other point you made, that is, it is important not to extend this analysis to the patients that have had prior atriopulmonary connections where there may be a higher incidence of thromboembolic events.
My last question is what do you tell families when they ask you "What is the incidence of Reyes syndrome, keeping a child on aspirin for many years?" Or is that a thing of the past? Thank you.
DR JACOBS: Yes, thats a very good question. Reyes syndrome is one of those things that saturated the pediatric and infectious disease medical literature, I think in the late 1970s and early 1980s, and has all but disappeared. And Im not sure whether its all but disappeared because of anything intelligent or therapeutic that were doing. Nonetheless, we do communicate with these patients general pediatricians and recommend that the aspirin therapy be interrupted in the course of a viral syndrome, or with exposure to varicella. I dont think that the interruption of aspirin therapy results in any kind of rebound phenomenon, or any kind of prothrombotic state, and it is known that the period of time during which the aspirin is discontinued is probably shorter than the period of time that platelet dysfunction from the effect of salicylates persists. Nonetheless, we do make that recommendation because of the association with Reyes syndrome.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. C. Odegard, D. Zurakowski, J. A. DiNardo, R. A. Castro, F. X. McGowan Jr., E. J. Neufeld, and P. C. Laussen Prospective longitudinal study of coagulation profiles in children with hypoplastic left heart syndrome from stage I through Fontan completion J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 934 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Jacobs, G. J. Pelletier, K. K. Pourmoghadam, C. I. Mesia, N. Madan, H. Stern, R. Schwartz, and J. D. Murphy Protocols associated with no mortality in 100 consecutive Fontan procedures Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 626 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakano, H. Kado, T. Tachibana, K. Hinokiyama, A. Shiose, M. Kajimoto, and Y. Ando Excellent Midterm Outcome of Extracardiac Conduit Total Cavopulmonary Connection: Results of 126 Cases Ann. Thorac. Surg., November 1, 2007; 84(5): 1619 - 1626. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S.D. Almond, J. E. Mayer Jr, R. R. Thiagarajan, E. D. Blume, P. J. del Nido, and D. B. McElhinney Outcome After Fontan Failure and Takedown to an Intermediate Palliative Circulation Ann. Thorac. Surg., September 1, 2007; 84(3): 880 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Petrossian, V. M. Reddy, K. K. Collins, C. B. Culbertson, M. J. MacDonald, J. J. Lamberti, O. Reinhartz, R. D. Mainwaring, P. D. Francis, S. P. Malhotra, et al. The extracardiac conduit Fontan operation using minimal approach extracorporeal circulation: early and midterm outcomes. J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1054 - 1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
B S Moffett, A L Parham, C D Caudilla, A R Mott, and K D Gurwitch Oral anticoagulation in a pediatric hospital: impact of a quality improvement initiative on warfarin management strategies. Qual. Saf. Health Care, August 1, 2006; 15(4): 240 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Alphonso, M. Baghai, P. Sundar, R. Tulloh, C. Austin, and D. Anderson Intermediate-term outcome following the fontan operation: a survival, functional and risk-factor analysis Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 529 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
H A Walker and M A Gatzoulis Prophylactic anticoagulation following the Fontan operation Heart, July 1, 2005; 91(7): 854 - 856. [Full Text] [PDF] |
||||
![]() |
C. Varma, M. R. Warr, A. L. Hendler, N. S. Paul, G. D. Webb, and J. Therrien Prevalence of "silent" pulmonary emboli in adults after the Fontan operation J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2252 - 2258. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |